Teladoc, Inc. (NYSE:TDOC) VP Mark Hirschhorn sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $34.04, for a total value of $340,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Mark Hirschhorn also recently made the following trade(s):

  • On Friday, September 22nd, Mark Hirschhorn sold 25,000 shares of Teladoc stock. The stock was sold at an average price of $31.93, for a total value of $798,250.00.

Shares of Teladoc, Inc. (NYSE TDOC) traded down 1.72% during trading on Thursday, reaching $34.20. The company’s stock had a trading volume of 236,804 shares. The company has a 50 day moving average of $33.26 and a 200-day moving average of $33.26. Teladoc, Inc. has a 12-month low of $14.00 and a 12-month high of $37.55. The stock’s market cap is $1.94 billion.

Teladoc (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.02). Teladoc had a negative return on equity of 19.88% and a negative net margin of 47.75%. The business had revenue of $44.60 million for the quarter, compared to the consensus estimate of $44.39 million. During the same period in the prior year, the business posted ($0.38) earnings per share. Teladoc’s revenue was up 68.3% on a year-over-year basis. Analysts forecast that Teladoc, Inc. will post ($1.44) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Marea Informative and is the property of of Marea Informative. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at http://www.mareainformativa.com/teladoc-inc-tdoc-vp-mark-hirschhorn-sells-10000-shares-of-stock/117440/.

Several hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its stake in shares of Teladoc by 134.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock worth $164,000 after acquiring an additional 2,707 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Teladoc by 101.9% during the 2nd quarter. California State Teachers Retirement System now owns 95,321 shares of the health services provider’s stock worth $3,308,000 after acquiring an additional 48,112 shares during the last quarter. Raymond James Financial Services Advisors Inc. bought a new stake in shares of Teladoc during the 2nd quarter worth approximately $202,000. The Manufacturers Life Insurance Company lifted its stake in shares of Teladoc by 132.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 41,270 shares of the health services provider’s stock worth $1,432,000 after acquiring an additional 23,553 shares during the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of Teladoc during the 2nd quarter worth approximately $2,316,000.

A number of analysts recently weighed in on the company. KeyCorp restated a “buy” rating and issued a $37.00 target price on shares of Teladoc in a research report on Sunday, September 17th. Robert W. Baird cut Teladoc from an “outperform” rating to a “neutral” rating and lifted their price target for the stock from $14.00 to $36.00 in a research note on Monday, September 18th. Chardan Capital lifted their price target on Teladoc from $30.00 to $41.00 and gave the stock a “buy” rating in a research note on Tuesday, June 20th. William Blair reaffirmed an “outperform” rating on shares of Teladoc in a research note on Tuesday, June 20th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $42.00 price target (up from $34.00) on shares of Teladoc in a research note on Tuesday, June 20th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Teladoc has an average rating of “Buy” and a consensus target price of $38.00.

About Teladoc

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Insider Buying and Selling by Quarter for Teladoc (NYSE:TDOC)

Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.